Display options
Cite
Pradhan A, Ganguly A, Naik MN, et al. Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent. Indian J Ophthalmol. 2020;68(8):1609-1614doi: 10.4103/ijo.IJO_1918_19.
Pradhan, A., Ganguly, A., Naik, M. N., Nair, A. G., Desai, S., & Rath, S. (2020). Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent. Indian journal of ophthalmology, 68(8), 1609-1614. https://doi.org/10.4103/ijo.IJO_1918_19
Pradhan, Anuradha, et al. "Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent." Indian journal of ophthalmology vol. 68,8 (2020): 1609-1614. doi: https://doi.org/10.4103/ijo.IJO_1918_19
Pradhan A, Ganguly A, Naik MN, Nair AG, Desai S, Rath S. Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent. Indian J Ophthalmol. 2020 Aug;68(8):1609-1614. doi: 10.4103/ijo.IJO_1918_19. PMID: 32709788; PMCID: PMC7640870.
Copy Download .nbib Format: NLM
Share it on

Indian J Ophthalmol. 2020 Aug;68(8):1609-1614. doi: 10.4103/ijo.IJO_1918_19.

Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent.

Indian journal of ophthalmology

Anuradha Pradhan, Anasua Ganguly, Milind N Naik, Akshay Gopinathan Nair, Savari Desai, Suryasnata Rath

Affiliations

  1. Ophthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, MTC Campus, Bhubaneswar, Odisha, India.
  2. Ophthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, KVC Campus, Vijayawada, Andhra Pradesh, India.
  3. Ophthalmic Plastic Surgery and Ocular Oncology Services, LV Prasad Eye Institute, KAR Campus, Hyderabad, Telangana, India.
  4. Department of Oculoplastic Surgery and Ocular Oncology: Aditya Jyot Eye Hospital, Wadala, Mumbai, Maharashtra, India.
  5. P.D Hinduja National Hospital, Mahim and Hinduja Healthcare Surgical, Mumbai, Maharashtra, India.

PMID: 32709788 PMCID: PMC7640870 DOI: 10.4103/ijo.IJO_1918_19

Abstract

PURPOSE: To evaluate the current practice patterns in the treatment of thyroid eye disease (TED) in Indian subcontinent through a web-based survey of members of Oculoplastics Association of India (OPAI).

METHODS: This was an online web-based questionnaire survey disseminated via monkeysurvey.com to all ratified active members of OPAI between May 1, 2016 and June 30, 2016. Questions encompassed the background, training, region, and experience of oculoplastic surgeons along with the management protocol of TED.

RESULTS: Of the 435 emails sent to OPAI members, 9 bounced and 180 (42.3%) responded within the study period. A large majority (96%) of respondents were oculoplastic surgeons practicing in India and the remaining practiced within South-East Asia. Two-thirds of respondents were oculoplastic surgeons with less than 10 years of clinical experience; 82% were fellowship trained in Oculoplasty. Almost all (99%) favored a multidisciplinary management of TED. A large majority routinely grade the severity (89%) and activity (87%) of disease before management. While corticosteroid remained the treatment of choice, 54% preferred immune-modulators as the second-line of therapy for recalcitrant TED. Three-quarters did not use orbital radiotherapy as a management modality in active TED owing to concerns over its efficacy and/or safety.

CONCLUSION: The survey gives useful insights to the practice patterns of TED management in Indian subcontinent. Multidisciplinary approach and grading of disease severity and activity were the rule rather than exception among OPAI members. Immune modulation was the preferred steroid-sparing agent in recalcitrant disease. Orbital radiotherapy was an uncommon treatment choice.

Keywords: India; orbital decompression; survey; thyroid eye disease

Conflict of interest statement

None

References

  1. J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40 - PubMed
  2. Ophthalmology. 2001 Sep;108(9):1523-34 - PubMed
  3. Ophthalmic Plast Reconstr Surg. 2015 Mar-Apr;31(2):127-31 - PubMed
  4. N Engl J Med. 1993 Nov 11;329(20):1468-75 - PubMed
  5. Ophthalmology. 2008 Feb;115(2):398-409 - PubMed
  6. Thyroid. 2004 May;14(5):403-6 - PubMed
  7. Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):805-15 - PubMed
  8. N Engl J Med. 2010 Feb 25;362(8):726-38 - PubMed
  9. Thyroid. 2008 Mar;18(3):333-46 - PubMed
  10. Br J Ophthalmol. 2004 Nov;88(11):1359-60 - PubMed
  11. Clin Endocrinol (Oxf). 1998 Jul;49(1):21-8 - PubMed
  12. Orbit. 2014 Oct;33(5):319-25 - PubMed
  13. J Clin Endocrinol Metab. 2003 Aug;88(8):3561-6 - PubMed
  14. J Clin Endocrinol Metab. 2004 Oct;89(10):5076-80 - PubMed
  15. Indian J Ophthalmol. 2012 Mar-Apr;60(2):87-93 - PubMed
  16. Thyroid. 2007 Apr;17(4):357-62 - PubMed
  17. Clin Endocrinol (Oxf). 2008 Dec;69(6):951-6 - PubMed
  18. Eye (Lond). 2013 Mar;27(3):308-19 - PubMed
  19. Clin Endocrinol (Oxf). 2005 Sep;63(3):323-8 - PubMed
  20. Ophthalmology. 2004 Aug;111(8):1557-62 - PubMed
  21. Eur Thyroid J. 2016 Mar;5(1):9-26 - PubMed
  22. Radiother Oncol. 1999 Dec;53(3):205-8 - PubMed
  23. Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596 - PubMed
  24. Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):192-7 - PubMed
  25. Eur J Endocrinol. 2006 Aug;155(2):207-11 - PubMed
  26. Radiother Oncol. 1996 Jan;38(1):69-71 - PubMed
  27. Curr Opin Ophthalmol. 2012 Sep;23(5):427-32 - PubMed

MeSH terms

Publication Types